{"id":"NCT00123474","sponsor":"Bristol-Myers Squibb","briefTitle":"Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML","officialTitle":"A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-07","primaryCompletion":"2006-09","completion":"2014-07","firstPosted":"2005-07-25","resultsPosted":"2015-08-26","lastUpdate":"2016-08-25"},"enrollment":724,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myeloid Leukemia, Chronic, Chronic-Phase"],"interventions":[{"type":"DRUG","name":"dasatinib","otherNames":["Sprycel","BMS-354825"]},{"type":"DRUG","name":"dasatinib","otherNames":["Sprycel","BMS-354825"]},{"type":"DRUG","name":"dasatinib","otherNames":["Sprycel","BMS-354825"]},{"type":"DRUG","name":"dasatinib","otherNames":["Sprycel","BMS-354825"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"},{"label":"4","type":"EXPERIMENTAL"}],"summary":"This is a phase III study of BMS-354825 in subjects with chronic phase Philadelphia chromosome or BCR-ABL positive chronic myelogenous leukemia, who are resistant or intolerant to imatinib mesylate (Gleevec).","primaryOutcome":{"measure":"Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up","timeFrame":"6 months","effectByArm":[{"arm":"QD Dasatinib","deltaMin":51.8,"sd":null},{"arm":"BID Dasatinib","deltaMin":49,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":137,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","Finland","France","Germany","Hungary","Ireland","Israel","Italy","Mexico","Netherlands","Norway","Peru","Philippines","Poland","Russia","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["19924787","19779040","18541900","27192969","24569263"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":75,"n":165},"commonTop":["Diarrhoea","Headache","Fatigue","Nausea","Cough"]}}